Scynexis, Inc.

Scynexis, Inc. is a biotechnology company focused on developing and commercializing innovative antifungal therapies for difficult-to-treat and often life-threatening infections. The company’s core expertise lies in novel oral and intravenous triterpenoid antifungals designed to address conditions such as vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis, and other refractory invasive fungal infections. By targeting serious fungal pathogens with differentiated mechanisms of action, Scynexis aims to serve patients with limited existing treatment options, including those who are immunocompromised or suffer from rare, severe infectious diseases. Its products and pipeline are positioned within the broader anti-infective and rare disease markets, working alongside hospitals, specialists, and infectious disease centers. Founded in 1999 and headquartered in Jersey City, New Jersey, Scynexis, Inc. operates as part of the global biopharmaceutical ecosystem, contributing specialized therapies that support clinicians in managing complex fungal infections across diverse care settings.